The impact of fractionation in SBRT: Analysis with the linear quadratic model and the universal survival curve model

References

• Lax I, Blomgren H, Näslund I, Svanström R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994;33:677–83.
   PubMed Web of Science ®Google Scholar
• Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995;34:861–70.
   Google Scholar
• Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27:3290–6.
   PubMed Web of Science ®Google Scholar
• Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657–64.
   PubMed Web of Science ®Google Scholar
• Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:847–52.
   PubMed Web of Science ®Google Scholar
• Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumours: Implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 2012;177:311–27.
   PubMed Web of Science ®Google Scholar
• Carlson DJ, Keall PJ, Loo BW, Chen ZJ, Brown JM. Hypofractionation results in reduced cell kill compared to conventional fractionation for tumours with regions of hypoxia. Int J Radiat Oncol Biol Phys 2011;79:1188–95.
   PubMed Web of Science ®Google Scholar
• Wennberg BM, Baumann P, Gagliardi G, Nyman J, Drugge N, Hoyer M, et al. NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. Acta Oncol 2011;50:518–27.
   PubMed Web of Science ®Google Scholar
• Thames HD, Withers HR, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982;8:219–26.
   PubMed Web of Science ®Google Scholar
• RTOG 0618 A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with operable stage I/II non-small cell lung cancer. Available from: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study = 0618 [cited August 2012].
   Google Scholar
• Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method. Int J Radiat Oncol Biol Phys 1989;16:1623–30.
   PubMed Web of Science ®Google Scholar
• Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985;8:13–9.
   PubMedGoogle Scholar
• Svedman C, Sandström P, Pisa P, Blomgren H, Lax I, Kälkner KM, et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006;45:870–5.
   PubMed Web of Science ®Google Scholar
• Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 2005;8:89–91.
   PubMed Web of Science ®Google Scholar
• Otsuka S, Shibamoto Y, Iwata H, Murata R, Sugie C, Ito M, et al. Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-pre-fraction irradiation in a murine tumor. Int J Radiat Oncol Biol Phys 2011;81:1538–43.
   PubMed Web of Science ®Google Scholar
• Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senen S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 2011;6:2036–43.
   PubMed Web of Science ®Google Scholar
• Astrahan M. Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation. Med Phys 2008;35:4161–72.
   PubMed Web of Science ®Google Scholar
• RTOG 0915 (NCCTG N0927). A randomized phase II study comparing 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Available from: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study = 0915 [cited August 2012].
   Google Scholar